NCT06903845Recruiting
APIXABAN App Study
The Effect of App. for Medication-check and Video-call Guided Education on APIXABAN Adherence in Patients of Atrial Fibrillation With Cardiac Disease: Randomised Control Pilot Study(APIXABAN Study)
Source: ClinicalTrials.gov · Last updated 6 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this clinical trial is to evaluate whether the medication reminder app and video call can improve medication adherence to apixaban in patients with AF and comorbidities. Patients with AF and comorbid heart disease taking apixaban who meet the inclusion criteria will be randomised 1:1 to a treatment arm using a medication reminder app and bi-weekly video education and a control arm using the medication reminder app alone to compare medication adherence. Patients in both groups will use the medication app, but only the treatment group will receive additional education and feedback via video call every two weeks to reinforce the use of the medication app and medication reminders with video education. The study aims to assess the change in adherence between the two groups at week 8.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 28 Mar 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Dong-Ju Choi
- Diseases
- Atrial fibrillation
- NCT number
- NCT06903845
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Mar 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Participants must meet all of the following criteria:
- Adults aged 19 years or older with a diagnosis of atrial fibrillation (AF)
- Presence of at least one of the following cardiovascular or metabolic comorbidities:
- Heart failure
- Hypertension
- Coronary artery disease
- Peripheral arterial disease
- Diabetes mellitus
- Stroke
- Other cardiac diseases requiring treatment
- Currently taking or planning to initiate oral anticoagulation therapy with apixaban
- Able to use a smartphone with an Android operating system
- Voluntarily provided written informed consent to participate in the clinical trial after being adequately informed of its purpose, procedures, and potential risks
- 2\. Exclusion Criteria
- Participants will be excluded if any of the following conditions apply:
- Creatinine clearance (CCr) \< 15 mL/min
- Presence of moderate to severe mitral stenosis
- History of mitral valve repair or replacement
- Clinically significant history of alcohol or substance abuse
- Deemed by the investigator to be legally or psychologically unsuitable for participation in the clinical trial
- Participation in another clinical trial involving investigational drugs within 4 weeks prior to screening
- Declines or is unwilling to provide informed consent for participation in this study
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.